DELFI Diagnostics, Inc.
DELFI's AI and whole-genome sequencing platform powers FirstLook Lung, a blood-based lung cancer screening test.
- Location
- —
- Roles tracked
- 0
- In pipeline
- 0
- Tracking since
- —
At a glance
You're tracking 0 roles at DELFI Diagnostics, Inc.. Track a role to start building momentum here.
Company intel
From the job board · LinkedIn data via posting sync- Industry
- Medical and Diagnostic Laboratories
- Company size
- 151 people
- Headquarters
- Palo Alto, California
- Founded
- 2019
- Type
- Privately Held
- Total funding
- $331.6M
DELFI uses AI, machine learning and whole genome sequencing to sensitively detect unique patterns of DNA fragmentation in the blood of patients with cancer.
Biotechnology
Clinical Trials
Clinical Research
Cancer Screening
Monitoring Research
Laboratory-Developed Tests
Liquid Biopsy Tests
AI and Machine Learning
Lung Cancer Screening
Early Cancer Detection
and Liquid Biopsy
